Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Dolutegravir Use During Pregnancy: What Are the Risks?

Infectious Disease Advisor spoke to Rebecca M. Zash, MD, a co-investigator of the interim analysis by the Tsepamo Study in Botswana, which was published in the New England Journal of Medicine in July.

Published
22 October 2018
From
Infectious Disease Advisor
‘Fear overcome by love’: why I participated in HIV cure research

Researchers may not know me, but they know my blood cells. I am participant 2512 of the Observational Study of the Consequences of the Protease Inhibitor Era (SCOPE). I was told that my case of HIV was discovered at the earliest stage of infection in history. This is not the life accomplishment that I would want to be remembered for. However, when I found out, I did want to help my fellow human beings.

Published
22 October 2018
From
Journal of Virus Eradication
Drug resistance accumulates fast in people with low but detectable viral loads, Kenyan study finds

A study measuring HIV drug resistance at two timepoints in Kenyan patients on second-line, protease inhibitor-based regimens has found very high levels of drug resistance in people with

Published
22 October 2018
By
Gus Cairns
ViiV Seeks FDA Approval for Two-Drug HIV Treatment

In clinical trials, the single-tablet regimen of Tivicay (dolutegravir) and Epivir (lamivudine) was as effective as a three-drug treatment.

Published
22 October 2018
From
Poz
Second case of potential HIV eradication

One of the highlights of the BHIVA Autumn Conference, slipped in as a couple of slides at the end of the meeting, was that the UK might have a second potential case of HIV eradication (although this is one of the presentations is one that is not online).

Published
22 October 2018
From
HIV i-Base
First HIV-positive to HIV-negative liver transplant raises intriguing questions for cure research

An HIV-negative child received a liver transplant from its HIV-positive mother and now appears to have no evidence of HIV infection apart from a very weak antibody

Published
19 October 2018
By
Keith Alcorn
Gilead and Aelix join forces to pursue HIV 'cure'

Gilead Sciences – already a giant in HIV therapy – has teamed up with Spanish biotech Aelix Therapeutics to try to develop a treatment regimen that would go beyond controlling the virus and provide an effective cure for the infection.

Published
18 October 2018
From
PMLiVE
Studies confirm long-term effectiveness of new single-tablet regimens

The newest once-daily, all-in-one HIV combination pills can maintain undetectable viral load for two years and counting, according to a set of studies presented at IDWeek 2018

Published
18 October 2018
By
Liz Highleyman
Rapid Initiation of HIV Care: Assessing Safety and Efficacy

Discussion with Gregory Huhn, MD

Published
16 October 2018
From
Infectious Disease Advisor
Wide range of views about switching to weekly, monthly or biannual ART

Two-thirds of people taking combination antiretroviral therapy (cART) would be interested in switching to a once-weekly oral regimen should it become available, according to American research published in

Published
15 October 2018
By
Michael Carter
← First12345...483Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.